MIRA INFORM
REPORT
|
Report Date : |
27.08.2011 |
IDENTIFICATION DETAILS
|
Name : |
LABORATORIOS IMA S.A.I.C. |
|
|
|
|
Registered Office : |
Palpa 2870/86 (1426)
Buenos Aires City |
|
|
|
|
Country : |
Argentina |
|
|
|
|
Financials (as on) : |
31.12.2010 |
|
|
|
|
Date of Incorporation : |
29.12.1961 |
|
|
|
|
Legal Form : |
Public Limited Company |
|
|
|
|
Line of Business : |
manufacture and commercialization
of medicinal products for human use |
RATING & COMMENTS
|
MIRA’s Rating : |
Ba |
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
Status : |
Satisfactory |
|
|
|
|
Payment
Behaviour : |
No Complaints |
|
|
|
|
Litigation : |
Clear |
NOTES :
Any query related to this report can be made
on e-mail : infodept@mirainform.com
while quoting report number, name and date.
ECGC Country Risk Classification List – March 31st, 2011
|
Country Name |
Previous Rating (31.12.2010) |
Current Rating (31.03.2011) |
|
Argentina |
b1 |
b1 |
|
Risk Category |
ECGC
Classification |
|
Insignificant |
A1 |
|
Low |
A2 |
|
Moderate |
B1 |
|
High |
B2 |
|
Very High |
C1 |
|
Restricted |
C2 |
|
Off-credit |
D |
Registered Name
LABORATORIOS IMA S.A.I.C.
C.U.I.T.: 30-50372092-9
Summary
INCORPORATED IN 1961. BEGINNER OF ACTIVITIES. BALANCE SHEET AS OF 31/12/2010.
NO NEGATIVE. FIT FOR CREDITS.
Line
of Business
MEDICINAL PRODUCTS
MANUFACTURE
COMMERCIALIZATION
Legal
Structure
Business type: Public Limited Company
Incorporation date: 29/12/1961
Duration: 99 years
End of fiscal year: 31/12
Registered in the AFIP Agency: 01/01/1957
Contact
Accountant: DANIEL SORSANA
Legal and Operative
Address: Palpa 2870/86 (1426) Buenos Aires City, Argentina.
Phone / Fax. (54-11)
4554-0507
email: administracion@laboratoriosima.com.ar
Board
of Directors
President:
JORGE MAURICIO JOSE ZAFFARONI
Vicepresident: AMALIA ALICIA BOSCACCI
Substitute Director: ELENA HERMINIA
BLANCO
Substitute
Director:
LILIAN NILDA ZAFFARONI
The first two mentioned
ones, as Legal Representatives, are in charge of the management and
administration of the company, with the use of the social signature.
Corporate
Stock
By General Ordinary and
Extraordinary Assembly dated on 24/04/2009, the share capital of the company
was increased to $ 5.000.000.- which was totally subscribed and paid-in.
Personal
Data
ZAFFARONI JORGE MAURICIO
JOSE
Argentine, married, CI 6.163.763, addressed at Jose Bonifacio 1870 floor
7 Department A, Buenos Aires City.
History
Laboratorios IMA S.A.I.C. (Industria
Medicinal Americana) is present in the national industry since 1982. It is
laboratory of medicinal specialities for human use, whose share capital is only
argentine.
There are no related
companies.
Finances
We have contacted to the
accountant Daniel Sorsana, who supplied some figures from the balance sheet
ended as of 31/12/2010, expressed in argentine pesos.
BALANCE SHEET ENDED AS OF
31/12/2010.
CURRENT ASSETS $
11.331.000.-
NON CURRENT ASSETS $ 5.902.000.-
TOTAL ASSETS $
17.233.000.-
CURRENT LIABILITIES $ 4.814.000.-
NON CURRENT
LIABILITIES $ 675.000.-
TOTAL LIABILITIES $ 5.489.000.-
NET WORTH
$ 11.744.000.-
NET SALES
$ 26.103.000.-
FINAL PROFIT $
3.768.000.-
Fixed
Assets
PROPERTIES:
The company owns the occupied premises which has a covered area of 1600
sqm. It has a good realization value because of its location.
VEHICLES:
1 car Peugeot 307, model
2010
They say that all their
properties are unencumbered.
Consulted
References
MAIN SUPPLIERS
AIR LIQUID ARGENTINA S.A.
CABELL S.A.
CHEMICAL CENTER S.R.L.
TERMS: Through installments
of 30/60/90 days
PRODUCTS: Raw material
AMOUNTS: u$s 1.000.000.- annual
with every supplier.
It is qualified as punctual in its payments.
Activity
This company is engaged in
the manufacture and commercialization of medicinal products for human use.
It produces pharmaceutical
forms which are injectable and cytostatic in small solutions and pharmaceutical
injectable freeze-dried forms.
Some of their main products
are as follows:
> CARBOPLATINO IMA
> CICLOFOSFAMIDA IMA
> DOXIMA
> DOXORUBICINA
> EPIRUBICINA IMA
> MITOMICINA C IMA
> ONDASETRON CEBEDOC
> VINORELBINA IMA
In 1997, IMA began to
register and commercialize its products exclusively in the foreign countries.
It certifies its plant for
the MERCOSUR, ANVISA and INVIMA.
In 2004, all areas in its production
plant was dedicated to the manufacture of oncological injectable freeze-dried
medicinal specialities and the ones in solution.
So, it modifies its
structure to be adapted to the national and international regulations.
It has areas qualified as class
A with environment B, which are engaged in the fractionation of injectable
medicinal products in solution, which are designed, operated and controlled
under proceedings based on national and international regulations what allow
them to obtain high quality products.
Its department in charge of
the quality control has sectors engaged in the physiochemical and
microbiological tests to do the verification of the quality specifications
established for the different stages involved in the manufacture of own
products for export as well as the control of proceedings in the production for
third parties.
Its products are developed
with requirements BPM and BPL.
They cover all the national
territory, exporting one part of its annual production to the MERCOSUR and
MEXICO.
At present, it employs 80
employees.
In the last twelve months
it carried out imports from the following countries:
> URUGUAY ZONA FRANCA U$S 83.514
> CHINA REP.POPULAR U$S 76.272
> ALEMANIA. R.FEDERAL U$S 66.718
> INDIA U$S
52.538
TOTAL : U$S 278.538
* 80 EMPLOYEES
Banks
BANCO PATAGONIA
BANCO MACRO
BANCO FRANCES
HSBC
Credit Risk: May 2011
BANCO PATAGONIA $ 1.708.200 Situation 1
BANCO MACRO $
117.600 Situation 1
BANCO FRANCES $ 6.400
Situation 1
HSBC $ 2.900
Situation 1
TOTAL $
1.955.100
Situation 1: Normal
fulfillment
IT DOES NOT REGISTER DISHONOURED CHECKS
Insurances
> MAPFRE S.A.
> FEDERACION PATRONAL
SEGUROS S.A.
> SMG SEGUROS S.A.
Payment
Record
Consulted sources say that this company has a good commercial concept because
of its good fulfillment of its commercial commitments.
It operates by amounts in
accordance with its resources without objections about it.
FULFILLMENT: WITHOUT
OBJECTIONS.
Final
Opinion
Because of the exposed information
we consider feasible the credit treatment with this company by moderate
amounts.
Anyway, we suggest the
request of additional guarantees.
FOREIGN EXCHANGE RATES
|
Currency |
Unit
|
Indian Rupees |
|
US Dollar |
1 |
Rs.46.05 |
|
UK Pound |
1 |
Rs.75.20 |
|
Euro |
1 |
Rs.66.48 |
RATING EXPLANATIONS
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
>86 |
Aaa |
Possesses an extremely sound financial base with the strongest
capability for timely payment of interest and principal sums |
Unlimited |
|
71-85 |
Aa |
Possesses adequate working capital. No caution needed for credit
transaction. It has above average (strong) capability for payment of interest
and principal sums |
Large |
|
56-70 |
A |
Financial & operational base are regarded healthy. General
unfavourable factors will not cause fatal effect. Satisfactory capability for
payment of interest and principal sums |
Fairly Large |
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
26-40 |
B |
Capability to overcome financial difficulties seems comparatively
below average. |
Small |
|
11-25 |
Ca |
Adverse factors are apparent. Repayment of interest and principal sums
in default or expected to be in default upon maturity |
Limited with
full security |
|
<10 |
C |
Absolute credit risk exists. Caution needed to be exercised |
Credit not
recommended |
|
---- |
NB |
New Business |
---- |
This score serves as a reference to assess SC’s credit risk
and to set the amount of credit to be extended. It is calculated from a
composite of weighted scores obtained from each of the major sections of this
report. The assessed factors and their relative weights (as indicated through
%) are as follows:
Financial
condition (40%) Ownership
background (20%) Payment
record (10%)
Credit history
(10%) Market trend
(10%) Operational
size (10%)
This report is issued at your request without any
risk and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL) or
its officials.